Phase II study of eribulin mesylate (E7389) in patients with metastatic castration-resistant prostate cancer stratified by prior taxane therapy

Bono, Johann S. de; Molife, L. Rhoda; Sonpavde, Guru; Maroto, José Pablo; Calvo, Emiliano; Cartwright, Thomas H.; Loesch, David; Feit, Kevie; Das, Asha; Zang, Edith; Wanders, J.; Agoulnik, Sergei; Petrylak, Daniel P.

doi:10.1093/annonc/mdr380

Cited by 56 publications

(36 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…No grade 3 peripheral neuropathy was observed in taxanenaive patients, whereas 6% of taxane-pretreated patients demonstrated this adverse effect. 55 …”

Section: Eribulin Mesylatementioning

confidence: 99%

Tubulin-Targeted Agents Including Docetaxel and Cabazitaxel

Cheetham

Petrylak²

2013

The Cancer Journal

View full text Add to dashboard Cite

Microtubules are dynamic filamentous cytoskeletal proteins that are responsible for cellular integrity and architecture, mitosis, intracellular transport, cell signaling, and gene expression. Tubulin exists in the cell as dimers of α and β subunits, which complexes with a variety of regulatory proteins. There is a dynamic equilibrium between free and polymerized tubulin causing a state called "dynamic instability," which is a target of anticancer drugs, which inhibit tubulin through polymerization (taxanes, epothilones) or depolymerization (vinca alkaloids). Docetaxel-based therapy was the first such treatment to demonstrate a survival benefit in men with castration-resistant prostate cancer. Cabazitaxel, an antitubulin agent, which demonstrates activity in multidrug- and docetaxel-resistant cancer cell lines, demonstrates a survival benefit over mitoxantrone and prednisone in patients who have failed docetaxel-based chemotherapy. This article reviews the use of antitubulin agents in patients with castration-resistant prostate cancer.

show abstract

“…No grade 3 peripheral neuropathy was observed in taxanenaive patients, whereas 6% of taxane-pretreated patients demonstrated this adverse effect. 55 …”

Section: Eribulin Mesylatementioning

confidence: 99%

Tubulin-Targeted Agents Including Docetaxel and Cabazitaxel

Cheetham

Petrylak²

2013

The Cancer Journal

View full text Add to dashboard Cite

show abstract

“…Another microtubule inhibitor, Eribulin mesylate, was tested in 108 patients, 50 of whom had previous taxane therapy. The PSA RR in taxane-naïve patients was 24 % but only 8.5 % in taxane pre-treated patients [71]. Lastly, a chemotherapeutic monomethyl auristatin E conjugated to an antibody aimed at the prostate antigen PSMA (PSMA-ADC) has been tested in a phase II trial in patients who have progressed on taxanes.…”

Section: Non-taxane Chemotherapeuticsmentioning

confidence: 99%

Chemotherapy in Prostate Cancer

Hurwitz

2015

Curr Oncol Rep

View full text Add to dashboard Cite

For approximately a decade, chemotherapy has been shown to prolong life in patients with metastatic castration-resistant prostate cancer (mCRPC). Since that time, however, only two agents have proven to prolong life (docetaxel and cabazitaxel). However, in the last year, the addition of chemotherapy to primary hormonal therapy became a standard of care for high-volume castration-sensitive metastatic disease. Here I will review current prostate cancer chemotherapies, mechanisms of resistance to those therapies, and ongoing clinical studies of chemotherapy combinations and novel chemotherapeutics.

show abstract

“…Treatment-related grade 3 and 4 toxicities were neutropenia (22.4%), leukopenia (8.6%), and fatigue (6.9%). 37 In a second multicenter trial (ECOG 5805), 119 patients (116 eligible) with metastatic CRPC were treated with eribulin at the same dose and on the same schedule. The primary endpoint was PSA response rate.…”

Section: Prostate Cancermentioning

confidence: 99%

Potential clinical applications of halichondrins in breast cancer and other neoplasms

Ortega¹,

Cortés²

2012

BCTT

View full text Add to dashboard Cite

Halichondrin B is a large polyether macrolide found in a rare Japanese sponge, Halichondria okadai and has been shown to have anticancer activity. Eribulin mesylate is a completely synthetic analog of halichondrin B with a unique mechanism of action relative to other antimicrotubule agents. This new agent has demonstrated activity in preclinical studies, and it is being developed for the treatment of different tumor types. Eribulin has been approved by the United States Food and Drug Administration and the European Medicines Agency as lateline therapy for metastatic breast cancer patients previously treated with an anthracycline and a taxane. It has demonstrated superiority over other treatments in overall survival (OS) (hazard ratio: 0.81, P = 0.041), leading to its regulatory approbation for clinical practice use. Median OS for the eribulin-treated group was 13.1 months versus 10.6 months in the physician's treatmentof-choice group. Eribulin demonstrated a manageable toxicity profile. Most common adverse events associated with treatment were mild neutropenia and fatigue, mainly of grade 1 or 2. In contrast to other antimicrotubule agents, eribulin has a relatively low incidence of peripheral neuropathy and alopecia. Eribulin has been extensively studied in breast cancer and is currently being developed for treatment of other cancer types. Eribulin has demonstrated activity in Phase II trials in non-small cell lung cancer, pancreatic cancer, urothelial tract cancer, and sarcomas. Further studies in these cancers are ongoing. This article reviews pharmacology, mechanism of action, pharmacokinetics and efficacy of eribulin in breast cancer and other neoplasms.

show abstract

Phase II study of eribulin mesylate (E7389) in patients with metastatic castration-resistant prostate cancer stratified by prior taxane therapy

Abstract: Eribulin mesylate demonstrated activity and a relatively favorable toxicity profile in metastatic CRPC.

Cited by 56 publications

References 25 publications

Tubulin-Targeted Agents Including Docetaxel and Cabazitaxel

Tubulin-Targeted Agents Including Docetaxel and Cabazitaxel

Chemotherapy in Prostate Cancer

Potential clinical applications of halichondrins in breast cancer and other neoplasms

Contact Info

Product

Resources

About